Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
Ann Rheum Dis. 2022;81(4):496–506 doi: 10.1136/annrheumdis-2021-221478
LN is one of the most prevalent severe disease manifestations of SLE, occurring in almost half of patients. As type I interferon is known to have a role in the pathogenesis of LN, there is scientific rationale to support anifrolumab, a human monoclonal antibody that binds to the type I interferon receptor subunit 1, as a potential LN treatment option.
To this end, Jayne, et al. aimed to assess the efficacy and safety of anifrolumab in patients with active, biopsy-proven, Class III/IV LN, in the phase II, TULIP-LN study.